Antioxidant eugenosedin-A protects against lipopolysaccharide-induced hypotension, hyperglycaemia and cytokine immunoreactivity in rats and mice

J Pharm Pharmacol. 2005 Jan;57(1):117-25. doi: 10.1211/0022357055137.

Abstract

Eugenosedin-A has been demonstrated to possess alpha/beta-adrenoceptor and serotonergic receptor blocking activities. We have investigated by what mechanisms eugenosedin-A prevents lipopolysaccharide (LPS)-induced hypotension, vascular hyporeactivity, hyperglycaemia, oxidative injury or inflammatory cytokines formation in rats. Intravenous administration of eugenosedin-A, trazodone, yohimbine (1 mg kg(-1)), aminoguanidine or ascorbic acid (15 mg kg(-1)) normalized LPS (10 mg kg(-1))-induced hypotension. Pretreatment with eugenosedin-A or the other agents 30 min before LPS injection reduced aortic hyporeactivity. LPS-induced increases in plasma interleukin-1beta (IL-beta), IL-6, interferon-gamma (IFN-gamma), tumour necrosis factor-alpha (TNF-alpha) and blood glucose levels were significantly inhibited by eugenosedin-A (1 mg kg(-1), i. v.). The same dose of trazodone, a chloropiperazinylbenzene-type antidepressant, and yohimbine, an alpha(2)-adrenoceptor antagonist, reduced IL-1beta and TNF-alpha, but it could not inhibit hyperglycaemia. Aminoguanidine, an inducible nitric oxide synthase (iNOS) inhibitor, and ascorbic acid, an antioxidant, decreased IL-1beta, TNF-alpha contents and hyperglycaemia. Eugenosedin-A and the other agents inhibited Fe(2+)-ascorbic acid-induced peroxidation in rat cortex, indicating that those agents had antioxidant effects, with the exception of aminoguanidine. In free radical scavenged experiments, eugenosedin-A and ascorbic acid eliminated peroxyl radicals. All test agents inhibited the LPS-induced increase of malondialdehyde (MDA) content in rat brain homogenates. When mice were administered an intraperitoneal injection of LPS alone, mortality occurred from 4 to 16 h, after which time all were dead. However, eugenosedin-A significantly prolonged the survival time after LPS injection, suggesting that eugenosedin-A protected against LPS-induced cardiovascular dysfunction, hyperglycaemia, tissue injury and inflammatory cytokine production. This was attributable mainly to the antioxidant and peroxyl radical scavenged effects of eugenosedin-A, and which may be, at least in part, due to its blockade on alpha/beta-adrenergic and serotonergic receptors.

MeSH terms

  • Animals
  • Antidepressive Agents, Second-Generation / pharmacology
  • Antioxidants / pharmacology*
  • Aorta, Thoracic / drug effects
  • Blood Glucose / metabolism
  • Cytokines / biosynthesis*
  • Cytokines / immunology
  • Free Radical Scavengers / pharmacology
  • Hyperglycemia / chemically induced
  • Hyperglycemia / prevention & control*
  • Hypotension / chemically induced
  • Hypotension / prevention & control*
  • In Vitro Techniques
  • Lipid Peroxidation / drug effects
  • Lipopolysaccharides / antagonists & inhibitors*
  • Lipopolysaccharides / toxicity
  • Mice
  • Mice, Inbred ICR
  • Oxidants / metabolism
  • Oxidative Stress / drug effects
  • Peroxides / metabolism
  • Piperazines / pharmacology*
  • Rats
  • Rats, Wistar
  • Survival Analysis
  • Trazodone / pharmacology

Substances

  • Antidepressive Agents, Second-Generation
  • Antioxidants
  • Blood Glucose
  • Cytokines
  • Free Radical Scavengers
  • Lipopolysaccharides
  • Oxidants
  • Peroxides
  • Piperazines
  • eugenosedin-A
  • Trazodone